title: Pharmacotherapy of suicidal behavior in bipolar disorder.
abstract: Patients with Bipolar Disorder (BD) are at particularly high risk for both attempted and completed suicides. The period of highest risk for completed suicide is during the 2 years following discharge from a hospitalization. To date, pharmacological studies of suicidal behavior in BD have been quite limited. While strong evidence has been found regarding the anti-suicidal effects of lithium, evidence for such properties in other commonly prescribed medications for BD, including anticonvulsants, SSRIs and anti-psychotics, has been largely unexplored. Considering the high risk of suicidal acts in patients with BD, further research on the pharmacotherapy of suicidal behavior is crucial.
authors: New York State Psychiatric Institute/Columbia University, Department of Neuroscience, New York 10032, USA. moquendo@neuron.cpmc.columbia.edu
authors: Maria A
authors: MA
authors: Oquendo
authors: Sadia R
authors: SR
authors: Chaudhury
authors: J John
authors: JJ
authors: Mann
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D013405:Suicide / Q000523:psychology*; D000092864:Suicide Prevention
chemical_list: D000927:Anticonvulsants; D014150:Antipsychotic Agents; D017367:Selective Serotonin Reuptake Inhibitors